CDMO Adare Pharma Solutions divests its postbiotic division

Adare Phar­ma So­lu­tions di­vest­ed a busi­ness that man­u­fac­tures post­bi­ot­ic prod­ucts to dsm-fir­menich, a Dutch man­u­fac­tur­er that sells a range of prod­ucts, in­clud­ing nu­traceu­ti­cals and vi­t­a­mins.

The con­tract man­u­fac­tur­er said the deal to di­vest Adare Bio­me is val­ued at €275 mil­lion ($300 mil­lion). Ac­cord­ing to the re­lease, dsm-fir­menich plans to ex­pand the avail­abil­i­ty of Adare Bio­me’s OTC post­bi­ot­ic sup­ple­ment known as Lac­téol and de­vel­op more post­bi­ot­ic prod­ucts.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN